H. Lundbeck A/S (Lundbeck) hereby publishes and reports a correction to a previous notification on transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck (Company Announcement No 795).
The original notification stated that 23,666,150 A-shares had been exchanged for a total of DKK 988,771,747.
H. Lundbeck A/S (Lundbeck) has subsequently received a revised notification confirming that 23,689,856 shares were exchanged for a total of DKK 989,762,183.68.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Lundbeckfond Invest A/S | |
| 2. | Reason for the notification | ||
| a) | Position/status | Closely associated party due to Lene Skole-Sørensen's capacity as Deputy Chair of H. Lundbeck A/S and CEO of Lundbeckfond Invest A/S as well as due to Lars Erik Holmqvist's capacity as member of the board of directors of H. Lundbeck A/S and Deputy Chair of Lundbeckfond Invest A/S. | |
| b) | Initial notification/Amendment | Amendment | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | H. Lundbeck A/S | |
| b) | LEI code | 5493006R4KC2OI5D3470 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | SharesDK0061804697 (A-shares)DK0061804770 (B-shares) | |
| b) | Nature of the transaction | Exchange of shares. The volume number indicated below is the number of Lundbeckfond Invest A/S' B-shares exchanged in return for other shareholders' A-shares at a 1:1 basis. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 41.78 | 23,689,856 | ||
| d) | Aggregated information - Aggregated volume - Price | Aggregated volume: 23,689,856Aggregated price of the transaction: DKK 989,762,183.68. | |
| e) | Date of the transaction | 2026-09-16 | |
| f) | Place of the transaction | Outside a trading venue | |
Closely associated persons/entities mean inter alia:
| Jens Høyer | Anders Crillesen |
| Vice President, Head of Investor Relations | Senior Director, External & Internal Relations |
| JSHR@lundbeck.com | AECE@lundbeck.com |
| +45 30 83 45 01 | +45 27 79 12 86 |
Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.
Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.
We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.
Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.